Drug · Other
Aflibercept
CI-DRUG-00000721Explore in graph →CHEMBL1742982 Approved
Regulatory
Approvals (16)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as ZALTRAP (DIN 02421089) under ATC L01XX44 AFLIBERCEPT. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Jul 13, 2020 | May 8, 2014 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as ZALTRAP (DIN 02421070) under ATC L01XX44 AFLIBERCEPT. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Jul 13, 2020 | May 8, 2014 | health-canada-dpd |
| EU EMA | Malignant Colorectal Neoplasm | Treatment of metastatic colorectal cancer (MCRC). | approved | Feb 1, 2013 | ema |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 14 days agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 3 | 2 | 1 | 11 | 74 | 16 | CA, EU, US | Nov 18, 2011 | 2001-11 |
| Malignant Kidney Neoplasm | Phase2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2007-12 |
| Malignant Ovarian Neoplasm | Phase2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2006-05 |
| Cutaneous Melanoma | Phase2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (75)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02298959 | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | active not recruiting | Phase 1 | 59 | National Cancer Institute (NCI)NIH | 2 | Jul 22, 2026 | clinicaltrials |
| NCT06121180 | Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | recruiting | Phase 2 |